Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd and rilvegostomig versus standard of care in advanced HER2-expressing biliary tract cancer
NL-OMON60678Phase 3Withdrawn
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in biliary cancer comparing Trastuzumab deruxtecan + rilvegostomig, Trastuzumab deruxtecan monotherapy and Standard of care (3 arms). Primary endpoint: Overall survival. Planned start May 2025; status: withdrawn.
02
Drugs
trastuzumab deruxtecanrilvegostomig
03
Conditions
biliary cancer
Beyond the preview
Go deeper on NL-OMON60678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60678.